Year All20242023202220212020201920182017201620152014 May 20, 2021 Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit May 05, 2021 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results May 04, 2021 Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome Apr 14, 2021 Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall Mar 09, 2021 Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference Mar 08, 2021 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome Mar 03, 2021 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results Feb 23, 2021 Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases Feb 05, 2021 Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome Jan 28, 2021 Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome
May 05, 2021 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 04, 2021 Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome
Mar 08, 2021 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
Mar 03, 2021 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
Feb 23, 2021 Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases
Feb 05, 2021 Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome
Jan 28, 2021 Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome